Worthing Fabian

Worthing Fabian is a Houston-based company that focuses on cancer research and the study of schizophrenia susceptibility genes. Their work centers around understanding the tumor microenvironment and cancer-associated fibroblasts, as well as investigating the cognitive behaviors associated with the deletion of the Ulk4 gene in mice.

With a timeline spanning from 2013 to 2023, Worthing Fabian has been actively engaged in cutting-edge research, aiming to unravel the complexities of cancer and schizophrenia. Their studies delve into the signaling pathways involved in abnormal cognitive behaviors and the impact of genetic factors on disease susceptibility.

Generated from the website